A Phase I clinical trial of rebecsinib, a first-in-class investigational drug targeting the ADAR1 gene involved in more than 20 types of cancer, has begun at UC San Diego. Developed by Dr. Catriona Jamieson and sponsored by Aspera Biomedicines, the trial is evaluating the drug in adults with relapsed or treatment-resistant acute myeloid leukemia (AML) and high-risk myelofibrosis, offering a potential new treatment for patients with limited therapeutic options.

Rebecsinib is the first ADAR1 inhibitor approved for clinical investigation and among the first experimental cancer drugs tested aboard the International Space Station (ISS). Space-based studies demonstrated that the drug effectively blocks ADAR1 activation, a key driver of cancer growth and immune evasion. Researchers believe the unique space environment accelerates disease processes, enabling faster evaluation of cancer biology and drug performance.

The ISS provides an exceptional research environment where microgravity and space-related stress accelerate cellular changes associated with aging and disease. This enables scientists to observe long-term biological processes in a much shorter timeframe than would be possible on Earth. By studying cancer cells and stem cells in space, researchers can better understand how tumors develop, evolve, and respond to new therapies, helping to accelerate the discovery of more effective treatments.

Beyond its potential for treating aggressive blood cancers, rebecsinib may have broader applications in precision medicine. Because ADAR1 plays a critical role in multiple solid and blood cancers—including ovarian, metastatic breast, brain, and lymphoid cancers—future clinical studies may expand to these diseases. Researchers are also exploring whether ADAR1 inhibition could help restore healthy stem cell function following prolonged space travel and provide new insights into age-related cellular degeneration.

The success of rebecsinib represents a significant milestone in translational medicine, demonstrating how discoveries made through laboratory research and space-based science can rapidly progress into human clinical trials. By combining advances in molecular biology, regenerative medicine, and space research, scientists are creating a new model for accelerating drug development and delivering innovative therapies to patients with urgent medical needs.

Source: https://today.ucsd.edu/area-story/rebecsinib-clinical-trial-means-new-options-for-blood-cancer